Drug Combination Details
| General Information of the Combination (ID: C33960) | |||||
|---|---|---|---|---|---|
| Name | Oroxylin A NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | XPC | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | ||
| A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | |||
| PLA-801D | CVCL_7110 | Lung giant cell carcinoma | Homo sapiens | |||
| PC-9 | CVCL_B260 | Lung adenocarcinoma | Homo sapiens | |||
| HCC827 | CVCL_2063 | Lung adenocarcinoma | Homo sapiens | |||
| NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1alpha mediated XPC transcription. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1alpha mediated XPC transcription. Oncogene. 2020 Nov;39(45):6893-6905. | |||
